The study by Fukuoka et al 1 published in Journal of Clinical Oncology in 2003 was a
randomized phase II study which investigated two doses of gefitinib (250 mg daily and 500 …

Objective To evaluate the safety and efficacy of gefitinib as second-line or even third-line
treatment for previously treated patients with locally advanced or metastatic non-small cell …

PURPOSE: This phase II single arm, open label study was designed to evaluate the efficacy
and toxicity of oral gefitinib (250mg) daily in previously untreated patients with advanced …

Objective To investigate the efficacy, time to progression, survival time and toxicity of
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target …

Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the data on the patient populations enrolled and the efficacy of erlotinib and gefitinib in the …

呼吸困难, 数小时后死亡, 死亡原因不明. 1 例为低分化鳞状细胞癌, 吸烟者,
肺部病灶及两肺转移灶消失后, 持续治疗 6 个月时出现脑转移, 经 γ-刀治疗后消失 …

• Epidermal growth factor receptor (EGFR) is an important target for anticancer therapy.
Monoclonal antibodies against EGFRs and small molecule inhibitors have entered clinical …

Background Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase
inhibitor with activity in previously treated patients with advanced-stage non-small-cell lung …

IN 1962, Stanley Cohen isolated a novel protein from the submaxillary gland of mice that
promoted accelerated eruption of incisors and eyelid opening in newborn animals. 1 Nearly …

Background The objective of this study was to evaluate the efficacy and toxicity of gefitinib as
a first-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Methods …